Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Overview of attention for article published in Blood, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets
blogs: 2 blogs
twitter: 51 X users

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 78 Mendeley

So far, Altmetric has seen 63 X posts from 51 X users, with an upper bound of 131,214 followers.

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study https://t.co/UZJznhJCCp Need to be better

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study https://t.co/SGtZNQIYVh

RT @smbenlazar: NPM1: the ultimate target in AML >> >>> Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myelo…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 59 additional X posts.